VTX2735 for Pericarditis
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it mentions that participants can be on stable doses of NSAIDs, colchicine, and/or oral corticosteroids.
How does the drug VTX2735 differ from other treatments for pericarditis?
The treatment of pericarditis typically involves non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine, with corticosteroids used in specific cases. VTX2735 may offer a novel approach, but specific details about its mechanism or benefits compared to existing treatments are not provided in the available research.12345
What is the purpose of this trial?
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP). Approximately 30 patients will take VTX2735.The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 6-week Open Label Treatment period (a participant receives active Dose A), a 7-week Extension Treatment period (a participant meets criteria for continuing and receives active Dose A) and a 14-day Follow-Up Period.
Research Team
Henrik Sonnergren, MD, PhD
Principal Investigator
Ventyx Biosciences
Eligibility Criteria
This trial is for individuals with Recurrent Pericarditis, which means they've had multiple episodes of pericarditis. Participants must pass a screening to qualify and be willing to take the study drug VTX2735 over several weeks.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive active Dose A of VTX2735
Extension Treatment
Participants meeting criteria continue receiving active Dose A
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- VTX2735
Find a Clinic Near You
Who Is Running the Clinical Trial?
Zomagen Biosciences Ltd.
Lead Sponsor